CA2518101A1 - Compositions and methods for the treatment of systemic lupus erythematosis - Google Patents

Compositions and methods for the treatment of systemic lupus erythematosis Download PDF

Info

Publication number
CA2518101A1
CA2518101A1 CA002518101A CA2518101A CA2518101A1 CA 2518101 A1 CA2518101 A1 CA 2518101A1 CA 002518101 A CA002518101 A CA 002518101A CA 2518101 A CA2518101 A CA 2518101A CA 2518101 A1 CA2518101 A1 CA 2518101A1
Authority
CA
Canada
Prior art keywords
polypeptide
pro
acid sequence
antibody
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002518101A
Other languages
English (en)
French (fr)
Inventor
Alexander Abbas
Sarah Bodary-Winter
Hilary Clark
Jill Schoenfeld
P. Mickey Williams
William I. Wood
Thomas D. Wu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2518101A1 publication Critical patent/CA2518101A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Cardiology (AREA)
  • Peptides Or Proteins (AREA)
CA002518101A 2003-03-03 2004-03-02 Compositions and methods for the treatment of systemic lupus erythematosis Abandoned CA2518101A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US45188403P 2003-03-03 2003-03-03
US60/451,884 2003-03-03
PCT/US2004/006460 WO2005051988A2 (en) 2003-03-03 2004-03-02 Compositions and methods for the treatment of systemic lupus erythematosis

Publications (1)

Publication Number Publication Date
CA2518101A1 true CA2518101A1 (en) 2005-06-09

Family

ID=34632721

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002518101A Abandoned CA2518101A1 (en) 2003-03-03 2004-03-02 Compositions and methods for the treatment of systemic lupus erythematosis

Country Status (6)

Country Link
US (2) US7749695B2 (enExample)
EP (1) EP1599498A2 (enExample)
JP (3) JP2008500009A (enExample)
AU (2) AU2004293369A1 (enExample)
CA (1) CA2518101A1 (enExample)
WO (1) WO2005051988A2 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020042062A1 (en) * 1999-09-24 2002-04-11 Mark Stearns Prostate cancer-related compositions, methods, and kits based on DNA macroarray proteomics platforms
US7790861B2 (en) * 1999-09-24 2010-09-07 Philadelphia Health And Education Corporation Prostate cancer-related compositions, methods, and kits based on DNA macroarray proteomics platforms
US7754435B2 (en) * 2000-09-21 2010-07-13 Philadelphia Health And Education Corporation Prostate cancer-related compositions, methods, and kits based on DNA macroarray proteomics platforms
WO2007043103A1 (ja) * 2005-09-30 2007-04-19 Kansai Technology Licensing Organization Co., Ltd. シェーグレン症候群診断法及び診断キット
CN101473045B (zh) 2006-04-24 2016-08-03 健泰科生物技术公司 用于检测自身免疫性病症的方法和组合物
US20100104581A1 (en) * 2006-05-25 2010-04-29 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods for Diagnosing and Treating Graft Rejection and Inflammatory Conditions
EP1905841A1 (en) * 2006-09-25 2008-04-02 Max Delbrück Centrum für Molekulare Medizin (MDC) Berlin-Buch; Trex1 as a marker for lupus erythematosus
WO2010011965A2 (en) * 2008-07-24 2010-01-28 The Regents Of The University Of California Identifying high risk clinically isolated syndrome patients
SMT201700063T1 (it) * 2009-09-03 2017-03-08 Medimmune Llc Diagnosi di interferoni di tipo 1
EP2621514B1 (en) 2010-09-28 2016-09-21 KAHR Medical (2005) Ltd Compositions and methods for treatment of hematological malignancies
DK2831109T3 (en) 2012-03-28 2018-02-12 Gadeta B V COMBINATORY GAMMA-9-DELTA-2-T-CELL RECEPTOR CHAIN EXCHANGE
ES2987986T3 (es) 2016-06-10 2024-11-18 Gadeta B V Nuevo método para identificar cadenas de receptores de células T delta (o células T gamma) o partes de estas que intervienen en una respuesta antitumoral o antiinfecciosa
EP3541407A1 (en) * 2016-11-18 2019-09-25 Universitat de Barcelona Combined cd6 and imipenem therapy for treatment of infectious diseases and related inflammatory processes
JP7136790B2 (ja) 2017-02-17 2022-09-13 ブリストル－マイヤーズ スクイブ カンパニー アルファ－シヌクレインに対する抗体およびその使用
BR112020013845A2 (pt) * 2018-01-09 2020-12-01 Imagine Pharma, Llc polipeptídeo ou formulação, métodos para modulação de crescimento celular endotelial e para tratamento de uma doença, e, uso de um polipeptídeo ou formulação.
GB202012804D0 (en) 2020-08-17 2020-09-30 Univ London Queen Mary Agrin polypeptide and uses thereof

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992016660A1 (en) * 1991-03-22 1992-10-01 Sloan-Kettering Institute For Cancer Research Methods for detection and treatment of cancer
WO2000015797A2 (en) * 1998-09-17 2000-03-23 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
WO2001040465A2 (en) * 1999-11-30 2001-06-07 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
KR20010103046A (ko) * 1999-03-08 2001-11-17 제넨테크, 인크. 면역 관련 질환 치료용 조성물 및 치료 방법
JP2002543764A (ja) * 1999-03-19 2002-12-24 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド ４６個のヒト分泌タンパク質
ES2333772T3 (es) * 1999-12-23 2010-03-01 Genentech, Inc. Polipeptidos homologos de il-17 y il-17r y sus utilizaciones terapeuticas.
AU2001234944A1 (en) * 2000-02-03 2001-08-14 Hyseq, Inc. Novel nucleic acids and polypeptides
CA2402525A1 (en) 2000-03-31 2001-10-11 Genentech, Inc. Compositions and methods for detecting and quantifying gene expression
US6436703B1 (en) 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
AU2001274888A1 (en) * 2000-05-19 2001-12-03 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
AU2001294943A1 (en) * 2000-10-02 2002-04-15 Bayer Corporation Nucleic acid sequences differentially expressed in cancer tissue
US20020137081A1 (en) * 2001-01-08 2002-09-26 Olga Bandman Genes differentially expressed in vascular tissue activation
EP1409677A2 (en) 2001-01-19 2004-04-21 Incyte Genomics, Inc. Receptors and membrane-associated proteins
WO2003010327A2 (en) * 2001-02-21 2003-02-06 Curagen Corporation Novel proteins and nucleic acids encoding same
AU2002324700A1 (en) * 2001-08-14 2003-03-03 Bayer Ag Nucleic acid and amino acid sequences involved in pain
US6489153B1 (en) * 2001-10-31 2002-12-03 Pe Corporation (Ny) Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof
US20040258678A1 (en) * 2002-02-22 2004-12-23 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
JP2004121218A (ja) * 2002-08-06 2004-04-22 Jenokkusu Soyaku Kenkyusho:Kk 気管支喘息または慢性閉塞性肺疾患の検査方法
US7118865B2 (en) * 2002-08-16 2006-10-10 Regents Of The University Of Minnesota Methods for diagnosing severe systemic lupus erythematosus
JP2006521082A (ja) 2002-09-11 2006-09-21 ジェネンテック・インコーポレーテッド 免疫関連疾患の治療のための新規組成物と方法
WO2004028479A2 (en) * 2002-09-25 2004-04-08 Genentech, Inc. Nouvelles compositions et methodes de traitement du psoriasis
CA2500687A1 (en) * 2002-10-02 2004-04-15 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
EP1578368A4 (en) * 2002-11-12 2008-01-23 Genentech Inc COMPOSITIONS AND METHOD FOR THE TREATMENT OF RHEUMATOID ARTHRITIS
EP1572116A4 (en) * 2002-11-26 2007-12-12 Genentech Inc COMPOSITIONS AND METHODS FOR THE TREATMENT OF IMMUNE DISEASES
WO2004076639A2 (en) * 2003-02-26 2004-09-10 Wyeth Use of gene expression profiling in the diagnosis and treatment of lupus nephritis and systemic lupus erythematosus

Also Published As

Publication number Publication date
AU2004293369A2 (en) 2005-06-09
AU2011202082A1 (en) 2011-05-26
WO2005051988A3 (en) 2005-07-28
JP2013240329A (ja) 2013-12-05
US7749695B2 (en) 2010-07-06
JP2010207229A (ja) 2010-09-24
US20090054300A1 (en) 2009-02-26
WO2005051988A2 (en) 2005-06-09
US20110142841A1 (en) 2011-06-16
EP1599498A2 (en) 2005-11-30
AU2004293369A1 (en) 2005-06-09
JP2008500009A (ja) 2008-01-10

Similar Documents

Publication Publication Date Title
US6262333B1 (en) Human genes and gene expression products
KR100607612B1 (ko) 종양의 진단 및 치료를 위한 방법 및 이를 위한 조성물
US20030219758A1 (en) Nucleic acids, proteins, and antibodies
US20020193567A1 (en) Secreted proteins and polynucleotides encoding them
ES2792126T3 (es) Método de tratamiento basado en polimorfismos del gen KCNQ1
CA3040194A1 (en) Compositions and methods for predicting response and resistance to ctla4 blockade in melanoma using a gene expression signature
US20020064818A1 (en) 52 human secreted proteins
EP0973899A2 (en) SECRETED EXPRESSED SEQUENCE TAGS (sESTs)
EP0973896A2 (en) SECRETED EXPRESSED SEQUENCE TAGS (sESTs)
KR20070100235A (ko) 종양의 진단 및 치료를 위한 조성물 및 방법
CN101874120A (zh) 作为用于乳腺癌风险评估、诊断、预后和治疗的标记的chr2和chr16的遗传性变型
US20040248256A1 (en) Secreted proteins and polynucleotides encoding them
CA2340616A1 (en) Secreted proteins and polynucleotides encoding them
KR20060015296A (ko) 신경교 기원의 종양의 진단 및 치료를 위한 조성물 및 방법
KR20040073537A (ko) 종양의 진단 및 치료 방법 및 이를 위한 조성물
WO2019018841A2 (en) COMPOSITIONS AND METHODS FOR IDENTIFICATION OF COMBINATORIAL IMMUNO-ONCOLOGIC THERAPEUTIC AGENTS
JP2002506625A (ja) サイトカインレセプター共通γ鎖様
US6225451B1 (en) Chromosome 11-linked coronary heart disease susceptibility gene CHD1
US20020065394A1 (en) Secreted proteins and polynucleotides encoding them
US20030027999A1 (en) 143 human secreted proteins
US20040018188A9 (en) Sparc-related proteins
US20020019000A1 (en) Polynucleotides coexpressed with matrix-remodeling genes
US12478665B2 (en) Cancer vaccine compositions and methods for using same to prevent and/or treat cancer
CA2416713A1 (en) Novel siglecs and uses thereof
US20040048304A1 (en) 95 human secreted proteins

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead

Effective date: 20170209